Ligand id: 7387

Name: lixisenatide

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Approved to control blood sugar levels in patients with type 2 diabetes, alongside diet and exercise and if required co-administered wiith other antidiabetes medicines.
A fixed-ratio formulation containing lixisenatide and insulin glargine is being evaluated in Phase 3 clinical trial for the treatment of type 2 diabetes (see NCT02787551).
Mechanism Of Action and Pharmacodynamic Effects
Acts as a GLP-1 receptor agonist and mimics the action of endogenous GLP-1 peptide in controlling blood sugar levels via improved insulin and glucagon secretion and decreased food intake.